Longevity & Cellular Health; Tissue Repair & Regeneration (Mitochondrial)
SS-31
A mitochondrial peptide signal for cristae and fatigue research.
Last updated
Mechanism
Binds cardiolipin, stabilizes cristae, and supports electron transport.
Reported effects
What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.
- Fatigue reduction
- HRV support
- Post-exertional malaise support
Dosing on file unverified
5-10 mg daily, cycled 8–12 weeks
| Reported dose | Volume | Draw |
|---|---|---|
| Low — 5 mg | 1 mL | 100 units |
| High — 10 mg | 2 mL | 200 units |
What that assumes. Assumes 10 mg in 2 mL (5000 mcg/mL) drawn on a U-100 barrel — the preset on this record, not a recommendation and not the only way to mix it. Change the vial mass, the diluent or the barrel and every number in this table changes. Run your own.
Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.
Reconstitution
| Vial | Diluent | Concentration | Typical dose | Draw |
|---|---|---|---|---|
| 10 mg | 2 mL | 5000 mcg/mL | 5000 mcg | 100 units |
mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.
Reported adverse effects
-
Injection site reactions
Literature on file 7
-
human RCT
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial (Neurology 2023) graded on: names a randomised controlled trial — “Randomized Clinical Trial”
-
animal in vivo
Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model. graded on: an animal model — “Rat”
-
human observational
NCT05168774: A Pilot Investigator Initiated Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide in the Treatment of Advanced Symptoms of Friedreich Ataxia (FRDA) graded on: a registered clinical study — “clinicaltrials.gov”
Not graded
4 citations whose study design could not be read from the title. Left ungraded rather than guessed at.
- not graded
- not graded
- not graded
- not graded
Identity
Skeletal formulathe canonical depiction
Drawn by PubChem from CID 11764719, the identifier on this record.
- Molecular weight
- 639.8
- Molecular formula
- C32H49N9O5
- CAS number
- 736992-21-5
- PubChem CID
- 11764719
- InChI key
- SFVLTCAESLKEHH-WKAQUBQDSA-N
- Sequence
- RXKF
- SMILES
- CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)N)C)O
- InChI
- InChI=1S/C32H49N9O5/c1-19-15-22(42)16-20(2)23(19)18-27(41-29(44)24(34)11-8-14-38-32(36)37)31(46)39-25(12-6-7-13-33)30(45)40-26(28(35)43)17-21-9-4-3-5-10-21/h3-5,9-10,15-16,24-27,42H,6-8,11-14,17-18,33-34H2,1-2H3,(H2,35,43)(H,39,46)(H,40,45)(H,41,44)(H4,36,37,38)/t24-,25+,26+,27+/m1/s1
Classified as
- Mitochondrial Cardiolipin Bindingmechanism
- It is unusually specific for this field: a named lipid, a named location, and a binding claim that can be tested directly. That is quite different footing from the broad mitochondrial support language elsewhere on the site.
- Mitochondrial Functionpathway
- The phrase appears in a great deal of product copy but is measured very differently across studies, from oxygen consumption in cultured cells to exercise capacity in a person, and the rung a claim earns usually depends on which was actually done.
- Subcutaneousroute
- This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.
- Intravenousroute
- A large share of the pharmacokinetic numbers attached to peptide records, half-life in particular, come from intravenous studies and often from animals. Those numbers describe an intravenous curve and do not transfer unchanged to a depot under the skin.
Also called
- 87GWG91S09
- Elamipretide
- MTP131
- SS-31
- SS-31 (Elamipretide) (Longevity)
- SS-31 (Elamipretide)
Notes unverified prose
Phase 3 MMPOWER-3 trial (40 mg/day SC); PROGRESS-HF; PMID: 37268435; Phase 3; MMPOWER-3; EMBRACE-STEMI; Phase 3 MMPOWER-3
Not on file 0
All 8 tracked fields hold a value on this record: molecular weight and formula, CAS number, PubChem CID, amino-acid sequence, SMILES, InChI and InChI key.
Counted from the record itself, not from what a source said it was missing. 136 of 185 records still have at least one empty.
Listed prices 4
What 4 shops we track listed for SS-31, read from their own public catalogues on 2026-08-12. We take no commission on these and they are not ranked by any payment — how vendors are scored.
| Vendor | Size | Price | Per mg |
|---|---|---|---|
| Ronin Peptides | 10 mg | $47.99 CAD | $4.80/mg |
| Amino Peptides | 10 mg | $79.99 CAD | $8.00/mg |
| Peptide Supply Online | size not listed | $75.00 CAD | — |
| Vendor | Size | Price | Per mg |
|---|---|---|---|
| Luxara Labs | size not listed | $55.00 USD | — |
None of these shops lists your destination. Choose “Show all” to see every listing we hold.
Prices are the vendor's own listing, reproduced with the date we read it — never converted between currencies, and compared per milligram only where the vendor states the vial size.
Share this record
